Antitumor Activity Of BRAF Inhibitor vemurafenib In ...
Combination trials with vemurafenib, in order to provide increased clinical benefit for patients with BRAF-mutated metastatic CRC. Materials and Methods vemurafenib. The clinical activity of vemurafenib in mCRC patients (albeit modest) supports ... Retrieve Content
Vemurafenib-associated Gingival Hyperplasia In Patient With ...
Vemurafenib-associated gingival hyperplasia in patient with metastatic melanoma exemplified by vemurafenib, the first Food BRAF inhibitor, is accompanied by specific toxicities. The most prominent side effect of vemurafenib both in preapproval clinical trials and postmarketing surveil- ... Access Full Source
Vemurafenib Resistance Mechanisms And Effects Of AT13387 In ...
Combining the HSP90 inhibitor, AT13387, with vemurafenib delays the emergence of resistance in a preclinical model of BRAFV600E mutant melanoma. ... Doc Viewer
Vemurafenib In Melanoma With BRAF V600E Mutation
Vemurafenib in Melanoma with BRAF V600E Mutation To the Editor: Figure 1. Clinical, Dermoscopic, treat for trials where the outcome is time to an event. BMJ 1999;319:1492-5. 2. ... Fetch Content
Kolltan Pharmaceuticals Provides Update On Clinical Pipeline, Corporate Developments And Near-Term Milestones
Kolltan Pharmaceuticals, Inc., a privately held clinical-stage company focused on the discovery and development of novel antibody-based drugs targeting receptor tyrosine kinases for use in oncology and immunology, today announced corporate developments, progress of the Company’s lead development programs and research pipeline and upcoming milestones. ... Read News
New Drugs Approved By The FDA In 2011 - About.com Money
Clinical Trials; FDA Approval; Insurance and Medicare/Medicaid; Manufacturing and Technology; Over-the-Counter Medicine; Philanthropy; Zelboraf (vemurafenib) and companion genetic test for late-stage melanoma, Roche; Zytiga (albiraterone acetate) ... Read Article
Information Regarding Clinical Trial - Highlands Oncology Group
Information Regarding Clinical Trial Sponsor Vemurafenib, and Vismodegib in Patients who have advanced solid tumors with mutations or gene expression abnormalities predictive of response to one of these agents. Protocol Number ML28897-PRO02 ... Fetch This Document
Corporate Medical Policy Ipilimumab (Yervoy) - BCBSNC
Corporate Medical Policy . Ipilimumab (Yervoy) File Name: ipilimumab_yervoy 6/2011 . 3/2015 . 3/2016 . 3/2015 . Ipilimumab is not covered in combination with Vemurafenib Some patients may be eligible for coverage under Clinical Trials. Refer to the policy on Clinical . Trial Services ... Return Document
Meghna Das Thakur, Et Al: Intermittent Vemurafenib May ...
AACR 2013 Pressconference April 7: Treatment and Resistance to Targeted Therapies Meghna Das Thakur, et al: Modeling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. ... View Video
An Open-label, Multicentre Safety Study Of vemurafenib In ...
An open-label, multicentre safety study of vemurafenib in patients in pivotal clinical trials,5–7 although this analysis is limited by the short duration of follow-up. Analyses • The final study analysis will be performed when tall patients enrolled ... View This Document
Molecular Testing For BRAF V600 Mutations In The BRIM-2 trial ...
The BRAF inhibitor vemurafenib (RG7204/PLX4032) in metastatic melanoma 1Medical Diagnostics, GE Healthcare, Aliso Viejo, CA; 2Esoterix Clinical Trial Services, Research Triangle Park, NC; 3Roche Molecular Systems, Pleasanton, CA Abstract #10523 ... Fetch Document
Personalizing Cancer Drug Trials: The MGH Experience - YouTube
Personalizing Cancer Drug Trials: The MGH Experience Dr. Antoni Ribas on Combining Vemurafenib and Ipilimumab for Metastatic Melanoma 8:35 Clinical Trials During and After Breast Cancer - Duration: 9:27. by Johns Hopkins Medicine 540 views. 9:27 Welcome to ... View Video
Safety And Efficacy Of vemurafenib In BRAF V600E Mutation ...
Vemurafenib, that was approved by Some randomized clinical trials focused on the significant reduction in the risk of death and disease progression associated with vemurafenib, compared with classical in BRAF V600E mutation-positive metastatic melanomas. Journal of ... Doc Retrieval
Hepatotoxicity With Combination Of Vemurafenib And Ipilimumab
Hepatotoxicity with Combination of Vemurafenib and Ipilimumab ther clinical development. Patients were eligible need for carefully conducted trials of new com-bination therapies, even when both agents have ... Read Here
Extended Antitumor Response Of A BRAF V600E Papillary Thyroid ...
For the latter, clinical trials are underway with vemurafenib as a treatment for metastatic PTC with BRAF V600E, and preliminary results are promising [10]. We report here a patient harboring BRAF V600E in Clinical trials have demonstrated a subset of melanoma patients harboring BRAF V600E ... Document Retrieval
202429Orig1s000 - Food And Drug Administration
The sponsor analyzed seven risks from the vemurafenib clinical trials for the level of risk mitigation needed. These risks include cutaneous squamous cell carcinoma (cuSCC), QT-prolongation, liver test abnormalities, photosensitivity, ... Return Doc
Imatinib - Wikipedia, The Free Encyclopedia
Imatinib , marketed by Novartis as Gleevec (Canada, Druker led the clinical trials confirming its efficacy in CML. The first clinical trial of Gleevec took place in 1998 and the drug received FDA approval in May 2001, ... Read Article
UNIFORM PHARMACY PRIOR AUTHORIZATION REQUEST FORM - RMHP
Zelboraf® (vemurafenib) meets the definition of medical necessity for the following: Malignant melanoma, unresectable, stage IIIC or metastatic, Mild to severe photosensitivity was reported in patients treated with vemurafenib in clinical trials. ... Access Content
Mitochondrial Oxidative Stress Is The Achille’s Heel Of ...
Mitochondrial oxidative stress is the achille’s heel of melanoma vemurafenib-resistant melanoma cells prone to cell death induced by pro-oxidants Results of phase II and III clinical trials with the ... Document Retrieval
Long-term Tolerability Of The BRAF Inhibitor vemurafenib In ...
Special report 1 3 Long-term tolerability of the BRAF inhibitor vemurafenib in patients with metastatic melanoma 181 Abstractemurafenib is a targeted therapy against V ... Retrieve Document
Two Novel Drugs Have Produced Unprecedented Gains In Survival ...
HEADLINE: Studies find new melanoma drugs boost survival CAPTION: Two novel drugs have produced unprecedented gains in survival in separate studies of people AS A MOTHER OF TWO SHE WAS DETERMINED TO LIVE AND WAS ACCEPTED INTO CLINICAL TRIALS FOR THE NEW DRUG VEMURAFENIB. SOT: ... View Video
A STATement On Vemurafenib-Resistant Melanoma
A STATement on Vemurafenib-Resistant Melanoma STAT3 inhibitors are currently being tested in clinical trials. Both autocrine and paracrine mechanisms may regulate STAT3–PAX3 signaling in response to RAF inhibitors. Clinical Implications of CD8 þ T-Cell ... Retrieve Content
Melanoma Brain Metastases And Vemurafenib: Need For Further ...
MELANOMA BRAIN METASTASES AND VEMURAFENIB Mayo Clin Proc. 979October 2012;87(10) imperative to conduct clinical trials that include pa-tients with metastatic brain disease to assess new drugs in this patient population. ACKNOWLEDGMENT ... Retrieve Full Source
No comments:
Post a Comment